These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26871512)

  • 1. Analysis of aDR5scFv with Specific Identification and Function.
    Cheng X; Meng Q; Gao C; Zhuang G; Huang X; Zhang J; Liu B; Fan X; Zhang M
    Monoclon Antib Immunodiagn Immunother; 2016 Feb; 35(1):25-31. PubMed ID: 26871512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
    Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
    Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
    Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice.
    Shi J; Liu Y; Zheng Y; Guo Y; Zhang J; Cheung PT; Xu R; Zheng D
    Cancer Res; 2006 Dec; 66(24):11946-53. PubMed ID: 17178893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
    Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
    IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
    Lei G; Xu M; Xu Z; Lu C; Tan S
    Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I.
    Luo Y; Pang H; Li S; Cao H; Peng Z; Fan C; Li S
    Cancer Biol Ther; 2009 Jul; 8(14):1369-77. PubMed ID: 19556853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a novel fully human monovalent antigen-binding fragment on the survival of cancer cell lines.
    Kwon YS; Lee YR; Kim YS; Lee HW; Jang YJ
    Oncol Rep; 2007 Aug; 18(2):513-7. PubMed ID: 17611678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-DR5 mAb ameliorate adjuvant arthritis rats through inducing synovial cells apoptosis.
    Li W; Liu Z; Zhuang G; Yin P; Tao H; Qiu J; Hu Q; Zhang J
    Exp Biol Med (Maywood); 2009 Dec; 234(12):1468-76. PubMed ID: 19934367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy.
    Wang W; He W; Wang L; Zhang G; Gao B
    Immunol Cell Biol; 2013 May; 91(5):360-7. PubMed ID: 23567896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
    Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
    IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of functional human monoclonal single-chain variable fragment antibody against HIV-1 from human cervical B cells.
    Berry JD; Rutherford J; Silverman GJ; Kaul R; Elia M; Gobuty S; Fuller R; Plummer FA; Barbas CF
    Hybrid Hybridomics; 2003 Apr; 22(2):97-108. PubMed ID: 12831535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.